US Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

被引:123
|
作者
Malik, Shakun M. [1 ]
Maher, Virginia Ellen [2 ]
Bijwaard, Karen E. [5 ]
Becker, Robert L. [5 ]
Zhang, Lijun [3 ]
Tang, Shenghui W. [3 ]
Song, Pengfei [4 ]
Liu, Qi [4 ]
Marathe, Anshu [4 ]
Gehrke, Brenda [2 ]
Helms, Whitney [2 ]
Hanner, Diane [2 ]
Justice, Robert [2 ]
Pazdur, Richard [2 ]
机构
[1] NCI, Clin Investigat Branch, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA
[2] US FDA, Off Hematol & Oncol Prod, Silver Spring, MD 20993 USA
[3] US FDA, Off Biostat, Silver Spring, MD 20993 USA
[4] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
[5] US FDA, Off In Vitro Diagnost & Radiol Hlth, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA
关键词
EML4-ALK FUSION GENE; ALK; CHEMOTHERAPY; EGFR;
D O I
10.1158/1078-0432.CCR-13-3077
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
On August 26, 2011, the U. S. Food and Drug Administration (FDA) approved crizotinib (XALKORI Capsules, Pfizer Inc.) for treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test. The Vysis ALK Break-Apart FISH Probe Kit (Abbott Molecular, Inc.) was approved concurrently. In two multicenter, single-arm trials, patients with locally advanced or metastatic ALK-positive NSCLC previously treated with one or more systemic therapies received crizotinib orally at a dose of 250 mg twice daily. In 119 patients with ALK-positive NSCLC by local trial assay, the objective response rate (ORR) was 61% [95% confidence intervals (CI), 52%-70%] with a median response duration of 48 weeks. In 136 patients with ALK-positive NSCLC by the to-be-marketed test, the ORR was 50% (95% CI, 42%-59%) with a median response duration of 42 weeks. The most common adverse reactions (>= 25%) were vision disorder, nausea, diarrhea, vomiting, edema, and constipation. Accelerated approval was granted on the basis of the high ORRs and durable responses. On November 20, 2013, crizotinib received full approval based on an improvement in progression-free survival in patients with metastatic ALK-positive NSCLC previously treated with one platinum-based chemotherapy regimen. Clin Cancer Res; 20(8); 2029-34. (C) 2014 AACR.
引用
收藏
页码:2029 / 2034
页数:6
相关论文
共 50 条
  • [21] UK and US Patient Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitors Treatments
    Culver, K. W.
    Montague, D.
    Le, H.
    Coulter, J.
    Cappelleri, J. C.
    Lu, H.
    Quaife, M.
    Meginnis, K.
    Fernandez, G.
    Vaghela, S.
    Rifi, N.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S706 - S707
  • [22] Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment
    Munarriz, Beatriz E. Jimenez
    Khan, Sam
    Li, Yuchen
    Ghazali, Nadia
    Liu, Geoffrey
    CANCER, 2025, 131
  • [23] FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
    Larkins, Erin
    Blumenthal, Gideon M.
    Chen, Huanyu
    He, Kun
    Agarwal, Rajiv
    Gieser, Gerlie
    Stephens, Olen
    Zahalka, Eias
    Ringgold, Kimberly
    Helms, Whitney
    Shord, Stacy
    Yu, Jingyu
    Zhao, Hong
    Davis, Gina
    McKee, Amye E.
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (21) : 5171 - 5176
  • [24] A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
    Riess, Jonathan W.
    Nagpal, Seema
    Neal, Joel W.
    Wake, Heather A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (04): : 389 - 394
  • [25] Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer
    Serritella, Anthony, V
    Bestvina, Christine M.
    THORACIC SURGERY CLINICS, 2020, 30 (02) : 137 - 146
  • [26] Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives
    Ryser, Christoph Oliver
    Diebold, Joachim
    Gautschi, Oliver
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 8 - 12
  • [27] Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
    Talreja, Vikas T.
    Noronha, Vanita
    Joshi, Amit
    Patil, Vijay
    Mahajan, Abhishek
    Prabhash, Kumar
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (04) : 211 - +
  • [28] Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion
    Pan, Yingying
    Xiao, Wenjing
    Ye, Feng
    Wang, Huijuan
    Shen, Yihong
    Yu, Xinmin
    Han, Xiao
    Chu, Qian
    Zhou, Caicun
    Zhang, Zhihong
    Ren, Shengxiang
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (12)
  • [29] Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)
    Solomon, B.
    Bang, Y. J.
    Camidge, D. R.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [30] Crizotinib In Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Curran, Monique P.
    DRUGS, 2012, 72 (01) : 99 - 107